Press Release

Advances progress towards planned Nasdaq uplisting POMPANO BEACH, Fla., July 10, 2026 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the…

Company Continues to Expand Intellectual Property Portfolio Supporting Advanced Placental Allograft Innovation POMPANO BEACH, FL / ACCESS Newswire / July 8, 2026 / BioStem Technologies, Inc. (OTCID:BSEM), a leading regenerative medicine company focused on…

POMPANO BEACH, Fla., June 10, 2026 — BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today…

The new independent directors strengthen the Company’s board as seasoned executives bring deep expertise in life sciences commercialization, healthcare administration, and investment management. POMPANO BEACH, Fla., June 09, 2026 (GLOBE…

POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) — BioStem Technologies Inc.(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today…

BioStem Technologies Expands Global Placental Allograft Patent Portfolio Pompano Beach, FL, May 20, 2026 (GLOBE NEWSWIRE) — BioStem Technologies®, a leading regenerative medicine company focused on developing and commercializing placental-derived…

POMPANO BEACH, Fla., May 12, 2026 — BioStem Technologies Inc.(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced…

POMPANO BEACH, Fla., March 31, 2026 — BioStem Technologies Inc.(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced…